Session

IBD (Posters)

EVALUATION OF THE HETEROGENEITY OF THE MANAGEMENT AND THE COMPLICATIONS OF CROHN'S DISEASE IN CATALONIA. A POPULATION QUALITY CARE STUDY
EVALUATION OF THE HETEROGENEITY OF THE MANAGEMENT AND THE COMPLICATIONS OF CROHN'S DISEASE IN CATALONIA. A POPULATION QUALITY CARE STUDY

FUNGAL MICROBIOTA IN THE ILEAL MUCOSA OF PATIENTS WITH CROHN'S DISEASE
FUNGAL MICROBIOTA IN THE ILEAL MUCOSA OF PATIENTS WITH CROHN'S DISEASE

EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL
EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL

CELLULAR IMMUNE RESPONSE TRIGGERED BY GRANULOCYTOAPHERESIS IN ULCERATIVE COLITIS PATIENTS UNDER BIOLOGICAL TREATMENT
CELLULAR IMMUNE RESPONSE TRIGGERED BY GRANULOCYTOAPHERESIS IN ULCERATIVE COLITIS PATIENTS UNDER BIOLOGICAL TREATMENT

PECULIARITIES OF FATTY ACID PROFILES OF ERYTHROCYTE MEMBRANES AND BLOOD SERUM DEPENDING ON ACTIVITY RATE OF CROHN’S DISEASE
PECULIARITIES OF FATTY ACID PROFILES OF ERYTHROCYTE MEMBRANES AND BLOOD SERUM DEPENDING ON ACTIVITY RATE OF CROHN’S DISEASE

IBD (Posters)  et al.

EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL
EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL

IBD (Posters)  et al.

FUNGAL MICROBIOTA IN THE ILEAL MUCOSA OF PATIENTS WITH CROHN’S DISEASE
FUNGAL MICROBIOTA IN THE ILEAL MUCOSA OF PATIENTS WITH CROHN’S DISEASE

IBD (Posters)  et al.

EVALUATION OF THE HETEROGENEITY OF THE MANAGEMENT AND THE COMPLICATIONS OF CROHN’S DISEASE IN CATALONIA. A POPULATION QUALITY CARE STUDY
EVALUATION OF THE HETEROGENEITY OF THE MANAGEMENT AND THE COMPLICATIONS OF CROHN’S DISEASE IN CATALONIA. A POPULATION QUALITY CARE STUDY

IBD (Posters)  et al.

EVALUATION OF THE EFFICACY OF TOFACITINIB AS MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY OCTAVE SUSTAIN BASELINE ENDOSCOPIC SUBSCORE
EVALUATION OF THE EFFICACY OF TOFACITINIB AS MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY OCTAVE SUSTAIN BASELINE ENDOSCOPIC SUBSCORE

IBD (Posters)  et al.

INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)
INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)

IBD (Posters)  et al.

COMPLETE ENDOSCOPIC HEALING IS ASSOCIATED WITH LOWER DISABILITY THAN PARTIAL MUCOSAL HEALING IN CROHN’S DISEASE: A PROSPECTIVE MULTICENTRIC STUDY
COMPLETE ENDOSCOPIC HEALING IS ASSOCIATED WITH LOWER DISABILITY THAN PARTIAL MUCOSAL HEALING IN CROHN’S DISEASE: A PROSPECTIVE MULTICENTRIC STUDY

IBD (Posters)  et al.

ARTIFICIAL INTELLIGENCE SURPASSES GASTROINTESTINAL EXPERTS IN THE CLASSIFICATION OF ENDOSCOPIC SEVERITY AMONG ULCERATIVE COLITIS
ARTIFICIAL INTELLIGENCE SURPASSES GASTROINTESTINAL EXPERTS IN THE CLASSIFICATION OF ENDOSCOPIC SEVERITY AMONG ULCERATIVE COLITIS

IBD (Posters)  et al.

EVALUATION OF A COMPUTATIONAL PLATFORM FOR PREDICTING TEMPORAL PROGRESSION OF MUCOSAL DAMAGE AND HEALING IN PATIENTS WITH CROHN’S DISEASE
EVALUATION OF A COMPUTATIONAL PLATFORM FOR PREDICTING TEMPORAL PROGRESSION OF MUCOSAL DAMAGE AND HEALING IN PATIENTS WITH CROHN’S DISEASE

IBD (Posters)  et al.

FEAR OF COVID-19 AMONG PERSONS WITH IBD ACCORDING TO EMPLOYMENT STATUS, EDUCATIONAL BACKGROUND AND RESIDENTIAL SETTING, AS COMPARED TO PERSONS WITH OTHER GASTROINTESTINAL CONDITIONS
FEAR OF COVID-19 AMONG PERSONS WITH IBD ACCORDING TO EMPLOYMENT STATUS, EDUCATIONAL BACKGROUND AND RESIDENTIAL SETTING, AS COMPARED TO PERSONS WITH OTHER GASTROINTESTINAL CONDITIONS

IBD (Posters)  et al.

TELEDERMA: TELEMEDICINE SYSTEM FOR DERMATOLOGICAL LESIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
TELEDERMA: TELEMEDICINE SYSTEM FOR DERMATOLOGICAL LESIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

EFFECTS OF COVID-19 ON EMPLOYMENT IN IBD PATIENTS
EFFECTS OF COVID-19 ON EMPLOYMENT IN IBD PATIENTS

IBD (Posters)  et al.

MENTAL HEALTH, WORK PRESENTEEISM AND EXERCISE IN IBD PATIENTS
MENTAL HEALTH, WORK PRESENTEEISM AND EXERCISE IN IBD PATIENTS

IBD (Posters)  et al.

QINGCHANG WENZHONG DECOCTION ACCELERATES INTESTINAL MUCOSAL HEALING THROUGH MODULATION OF DYSREGULATED GUT MICROBIOTA IN DSS-INDUCED COLITIS MICE
QINGCHANG WENZHONG DECOCTION ACCELERATES INTESTINAL MUCOSAL HEALING THROUGH MODULATION OF DYSREGULATED GUT MICROBIOTA IN DSS-INDUCED COLITIS MICE

IBD (Posters)  et al.

PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD (APD334) IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY
PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD (APD334) IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY

IBD (Posters)  et al.

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM
NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

IBD (Posters)  et al.

Item 281 - 300 / 568
1 2 3 4 5 6 7 8 9 10 11 12 13 14
15
16 17 18 19 20 21 22 23 24 25 26 27 28 29